Sabby Management’s Nabriva Therapeutics plc Ordinary Shares Ireland NBRV Stock Holding History

Sabby Management’s Portfolio NBRV Stock Details NBRV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-2,682	Closed	-$40K	–	212
2021 Q4	$40K	Buy	2,682 +1,213	+83%	+$28.7K	0.01%	173
2021 Q3	$44K	Sell	1,469 -842	-36%	-$23.8K	0.01%	171
2021 Q2	$78K	Sell	2,311 -4,249	-65%	-$158K	0.01%	153
2021 Q1	$272K	Sell	6,560 -3,840	-37%	-$239K	0.05%	124
2020 Q4	$629K	Buy	10,400 +9,328	+870%	+$1.01M	0.12%	60
2020 Q3	$143K	Buy	+1,072	New	+$179K	0.02%	109
2020 Q2	–	Sell	-1,470	Closed	-$211K	–	140
2020 Q1	$211K	Sell	1,470 -2,673	-65%	-$818K	0.09%	53
2019 Q4	$1.37M	Buy	+4,143	New	+$1.9M	0.38%	15
2018 Q1	–	Sell	-40	Closed	-$60K	–	203
2017 Q4	$60K	Buy	+40	New	+$63.3K	0.01%	139

Other funds holding NBRV

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

AICPI

ABG Innovation Capital Partners III Central, Hong Kong, Hong Kong $64.5K AUM 1.01% 1-Year Est. Return

VFA

Values First Advisors Gray, Tennessee $192M AUM 24.96% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Sabby Management's NBRV Position: Q1 2022 in Review

Sabby Management sold out of Nabriva Therapeutics plc Ordinary Shares Ireland (NBRV) in Q1 2022, closing a stake of 2,682 shares — an estimated $40K sold.

Sabby Management first reported a position in NBRV in Q4 2017 and held it in 9 quarters. The position peaked at $1.37M in Q4 2019. 29 funds tracked by Wall St. Rank hold NBRV as of Q1 2022.

Sabby Management reported no remaining Nabriva Therapeutics plc Ordinary Shares Ireland position as of Q1 2022 after selling out during the quarter.
Sabby Management sold 2,682 Nabriva Therapeutics plc Ordinary Shares Ireland shares in Q1 2022, an estimated $40K.
Sabby Management first reported a position in Nabriva Therapeutics plc Ordinary Shares Ireland in Q4 2017 and held it in 9 quarters.
Sabby Management's Nabriva Therapeutics plc Ordinary Shares Ireland position peaked at $1.37M in Q4 2019.
29 funds tracked by Wall St. Rank held Nabriva Therapeutics plc Ordinary Shares Ireland as of Q1 2022.

Based on Sabby Management's 13F filing for Q1 2022, filed 16 May 2022.